X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs ORCHID PHARMA LTD - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD ORCHID PHARMA LTD ALEMBIC LTD/
ORCHID PHARMA LTD
 
P/E (TTM) x 58.4 -0.2 - View Chart
P/BV x 2.4 0.2 1,552.3% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 ALEMBIC LTD   ORCHID PHARMA LTD
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
ORCHID PHARMA LTD
Sep-13
ALEMBIC LTD/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs72194 37.1%   
Low Rs3435 96.9%   
Sales per share (Unadj.) Rs4.7276.5 1.7%  
Earnings per share (Unadj.) Rs6.1-79.2 -7.7%  
Cash flow per share (Unadj.) Rs6.2-43.5 -14.4%  
Dividends per share (Unadj.) Rs0.200-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs40.753.9 75.4%  
Shares outstanding (eoy) m267.0370.45 379.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x11.30.4 2,719.9%   
Avg P/E ratio x8.7-1.4 -600.1%  
P/CF ratio (eoy) x8.5-2.6 -321.7%  
Price / Book Value ratio x1.32.1 61.3%  
Dividend payout %3.30-   
Avg Mkt Cap Rs m14,1398,067 175.3%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m2072,527 8.2%   
Avg. sales/employee Rs ThNM6,956.1-  
Avg. wages/employee Rs ThNM902.5-  
Avg. net profit/employee Rs ThNM-1,993.0-  
INCOME DATA
Net Sales Rs m1,25519,477 6.4%  
Other income Rs m370407 90.9%   
Total revenues Rs m1,62519,884 8.2%   
Gross profit Rs m1111,103 10.1%  
Depreciation Rs m382,519 1.5%   
Interest Rs m25,227 0.0%   
Profit before tax Rs m442-6,236 -7.1%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m24-125 -19.1%   
Profit after tax Rs m1,630-5,580 -29.2%  
Gross profit margin %8.95.7 156.4%  
Effective tax rate %5.42.0 270.0%   
Net profit margin %129.8-28.7 -453.2%  
BALANCE SHEET DATA
Current assets Rs m1,86711,014 17.0%   
Current liabilities Rs m59132,060 1.8%   
Net working cap to sales %101.6-108.1 -94.1%  
Current ratio x3.20.3 919.3%  
Inventory Days Days9495 99.3%  
Debtors Days Days7434 219.2%  
Net fixed assets Rs m1,79129,440 6.1%   
Share capital Rs m534705 75.8%   
"Free" reserves Rs m10,3242,043 505.4%   
Net worth Rs m10,8583,800 285.7%   
Long term debt Rs m419,018 0.5%   
Total assets Rs m11,59146,510 24.9%  
Interest coverage x260.9-0.2 -135,088.2%   
Debt to equity ratio x02.4 0.2%  
Sales to assets ratio x0.10.4 25.9%   
Return on assets %14.1-0.8 -1,852.1%  
Return on equity %15.0-146.9 -10.2%  
Return on capital %15.2-3.7 -406.7%  
Exports to sales %1.537.9 4.1%   
Imports to sales %21.022.6 92.7%   
Exports (fob) Rs m197,378 0.3%   
Imports (cif) Rs m2634,406 6.0%   
Fx inflow Rs m197,513 0.3%   
Fx outflow Rs m2645,649 4.7%   
Net fx Rs m-2441,865 -13.1%   
CASH FLOW
From Operations Rs m2361,682 14.0%  
From Investments Rs m-224-9,860 2.3%  
From Financial Activity Rs m-276,644 -0.4%  
Net Cashflow Rs m-15-1,535 1.0%  

Share Holding

Indian Promoters % 64.0 32.3 198.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 4.6 4.3%  
FIIs % 9.7 3.3 293.9%  
ADR/GDR % 0.0 4.6 -  
Free float % 26.1 55.3 47.2%  
Shareholders   54,701 84,811 64.5%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare ALEMBIC LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Sep 19, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 5-YR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS